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Treatment Pathway of Bone Sarcoma in Children,
Adolescents, and Young Adults
Damon R. Reed, MD 1,2,3; Masanori Hayashi, MD4; Lars Wagner, MD5; Odion Binitie, MD1,3,6; Diana A. Steppan, MD4;
Andrew S. Brohl, MD1,2; Eric T. Shinohara, MD, MSCI7; Julia A. Bridge, MD8; David M. Loeb, MD, PhD4;
Scott C. Borinstein, MD, PhD 9; and Michael S. Isakoff, MD10
When pediatric, adolescent, and young adult patients present with a bone sarcoma, treatment decisions, especially after relapse, are
complex and require a multidisciplinary approach. This review presents scenarios commonly encountered in the therapy of bone sar-
comas with the goal of objectively presenting a consensus, multidisciplinary management approach. Little variation was found in the
authors’ group with respect to local control or systemic therapy. Clinical trials were universally prioritized in all settings. Decisions re-
garding relapse therapies in the absence of a clinical trial had very minor variations initially, but a consensus was reached after a liter-
ature review and discussion. This review presents a concise document and figures as a starting point for evidence-based care for
patients with these rare diseases. This framework allows prospective decision making and prioritization of clinical trials. It is hoped
that this framework will inspire and focus future clinical research and thus lead to new trials to improve efficacy and reduce toxicity.
Cancer 2017;123:2206-18. VC 2017. The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This
is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use
and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adap-
tations are made.
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INTRODUCTION
The most common malignancies of bone in the first 3 decades of life are osteosarcoma, Ewing sarcoma, and chondrosar-
coma. The treatment of these tumors is complex, and management decisions are best made in a multidisciplinary environ-
ment with input from experienced orthopedists, radiotherapists, radiologists, pathologists, and oncologists.
Several factors, including the variability in primary tumor locations, sites and extent of metastatic disease, feasibility of
surgical resection, molecular features, growth rate, and histologic variation, complicate care for these relatively rare cancers.
Although there are many case reports, retrospective studies, and review articles, there are few prospective, randomized trials
beyond first-line therapy to guide clinical decisions for individual patients with bone sarcoma, and this increases the relative
value of expert opinion. There also may be a reluctance from experts to comment on the care of more complicated patients
with whom they are not directly involved, and sometimes not all of the relevant patient-specific details are considered when
treatment options are offered. Available therapy guidelines often simply list options and include all reasonable therapy possi-
bilities rather than suggesting a specific course.1 In the relapsed setting, data to inform decisions are evenmore limited and of-
ten come from small, single-arm clinical trials without a perspective on how treatments should be prioritized or even if they
should be considered at all. Finally, although these tumors are often considered pediatric neoplasms, the peak incidence is in
teenagers and young adults, whomay be managed by physicians less familiar with these rare tumors.
Here we address select scenarios to highlight consensus treatment approaches. We also emphasize the importance of
enrolling patients into clinical trials. Because the purpose of this article is to propose a treatment pathway rather than
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provide a comprehensive review of the field, we apologize
in advance to the many authors whose important contri-
butions could not be cited because of word limitations. In
addition, we recognize that our recommendations include
off-label uses of many agents, and for that reason, they
should be applied with the understanding that they are often
based on small published trials and not on the same rigorous
level of evidence required for Food and Drug Administra-
tion approval. Although variations in recommendations for
care certainly exist, we found surprisingly little disagreement
among the members of our group.We expect that our path-
way will lead to clearer decisions on treatment options for
patients and physicians throughout the greater oncology
community. We anticipate disagreements with some rec-
ommendations and view the resulting discussions as oppor-
tunities for clinical investigation. We hope that this
approach will help to focus future research on important
unsolved management questions, maximize clinical trial
enrollment, andminimize off-label use of ineffective agents.
METHODS
This project began at the February 2016 National Pediat-
ric Cancer Foundation’s Sunshine Project retreat when we
were discussing appropriate prioritization of phase 1 and
2 clinical trials for relapsed sarcoma patients. We recog-
nized that no comprehensive list of agents and clinical
outcome data existed to help drive decision making, and
we thus set out to develop a consensus pathway for treat-
ing common pediatric, adolescent, and young adult bone
sarcomas. We diagramed our opinions into a pathway
covering the initial workup, the importance of multidisci-
plinary therapy, the role of clinical trials, the communica-
tion of risk and long-term toxicities, the approaches to
surveillance, and the best established therapies for relapsed
disease. Teleconferences were convened biweekly over the
course of 6 months.
Question 1: What Is the Appropriate Initial
Workup of a Bone Sarcoma?
Most patients with a bone sarcoma present with swelling
or pain that waxes and wanes; it classically wakes the pa-
tient from sleep at night and occasionally culminates in a
pathologic fracture. The initial evaluation (Fig. 1) would
typically include plain films revealing an aggressive lesion
and prompt a referral to an orthopedic surgeon with ma-
lignant bone tumor expertise. Additional imaging with
magnetic resonance imaging of the entire bone of concern
is necessary to demonstrate the extent and characteristics
of the lesion and to evaluate the patient for skip lesions.
Next, a core-needle biopsy or an open biopsy should be
considered. For challenging anatomic locations, interven-
tional radiographic techniques may be incorporated.
Our consensus is that either technique is acceptable. We
typically pursue a core biopsy to minimize patient morbidi-
ty, although because of the more limited sampling, this
technique occasionally may not provide sufficient material
for a diagnosis or research studies. Once the diagnosis is
confirmed, the proper staging and treatment can be deter-
mined. In addition, consideration at this point should be
given to genetic testing or counseling and also to supportive
care consultations (eg, for fertility preservation). We ac-
knowledge that the workup is similar to that described in
the National Comprehensive Cancer Network guidelines.
It differs by providing more detail, omitting lactate dehy-
drogenase, specifically mentioning the biopsy method, and
also not including consideration of a computed tomogra-
phy scan of the primary tumor site.
Question 2: What Is Needed to Accurately
Diagnose and Stage a Newly Diagnosed
Osteosarcoma Patient?
Once osteosarcoma is diagnosed, the extent of disease must
be determined (Fig. 1). In preparation for potential chemo-
therapy toxicity, standard baseline organ assessments
should be obtained (Fig. 1). Effective communication of
the long-term risks of therapy, including the risks of infer-
tility, cardiotoxicity, and/or second cancers, is needed be-
fore the initiation of therapy. Chemotherapy and surgical
options, including clinical trial options, should be discussed
as part of the informed consent process.
Question 3: What Is the Best Initial
Treatment Strategy for a Newly Diagnosed
Osteosarcoma Patient?
Osteosarcoma is the most common primary malignant
bone tumor in children, adolescents, and young adults.
The current standard of care for localized osteosar-
coma is neoadjuvant chemotherapy followed by complete
surgical resection of the primary disease and then adjuvant
chemotherapy, ideally in a clinical trial when one is avail-
able (Fig. 2). We recommend methotrexate, doxorubicin,
and cisplatin (MAP) chemotherapy for the first-line treat-
ment, as reinforced by previous clinical trials.2,3 Some
studies questioned the addition of methotrexate; however,
high-dose methotrexate is now included as standard thera-
py since subsequent studies have demonstrated a benefit.4
In addition, standard MAP therapy includes a cumulative
doxorubicin dose of 450mg/m2, which is higher than the
300mg/m2 threshold commonly considered to place
patients at risk for long-term cardiotoxicity. Our consen-
sus regarding cardioprotection is to use dexrazoxane with
Consensus Bone Sarcoma Treatment Pathway/Reed et al
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bolus-dose doxorubicin on days 1 and 2 when the dose of
doxorubicin is in excess of 300mg/m2. An alternative and
acceptable plan is to use dexrazoxane with all doses of
doxorubicin, although we recognized in discussion that
universal acceptance of this has not yet been achieved
among all authors. A continuous infusion of doxorubicin
has been advocated by some when dexrazoxane is not be-
ing used, although conflicting data regarding the efficacy
in preventing cardiotoxicity have led some to not use this
approach.5,6 Although there are no data regarding the
optimal timing of local control, most teams recommend
two 5-week cycles of neoadjuvant MAP therapy, which
Figure 1.Workup for newly suspected bone sarcoma. CBC indicates complete blood count; CMP, complete metabolic panel; CT,
computed tomography; GFR, glomerular filtration rate; LDH, lactate dehydrogenase; MRI, magnetic resonance imaging; PET, posi-
tron emission tomography.
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Figure 2. Pathway for treating newly diagnosed and relapsed osteosarcoma. CIVI indicates continuous intravenous infusion; CR,
complete response; IE, ifosfamide and etoposide; MAP, methotrexate, doxorubicin, and cisplatin; PD, progressive disease; PR, par-
tial response; SD, stable disease.
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can facilitate limb salvage.7 For curative intent, regard-
less of location, complete surgical resection of all disease
must be the goal. In the appendicular skeleton, limb-
preserving resection and reconstruction with endopros-
theses and, in some sites, an allograft or rotationplasty
are the standard of care. An amputation may be per-
formed when the limb cannot be preserved or in cases in
which the functional outcome may be improved by this
technique. The combination of improved imaging mo-
dalities, the standard use of neoadjuvant chemotherapy,
and the advancement of complex surgical techniques has
led to higher limb-salvage rates.8 Surgical local control
for an axial skeleton osteosarcoma is complex, and when
the disease is not amenable to surgical resection or the
margins are positive, radiation therapy has been shown
to improve local control rates.9 Higher total radiation
doses or hypofractionation (larger daily doses) may im-
prove local control. Stereotactic radiosurgery may allow
shorter courses of treatment while still providing durable
local control.10
Tumor necrosis after neoadjuvant chemotherapy has
prognostic significance.11 Although different histopatho-
logic subtypes of high-grade, intraosseous conventional
osteosarcoma have been identified (eg, osteoblastic, chon-
droblastic, and fibroblastic), no relation between these
subtypes and the treatment or prognosis appears to ex-
ist.12 Recently, the European and American Osteosarco-
ma Study (EURAMOS) group completed a large phase 3,
randomized study that failed to demonstrate improved
event-free survival by modifying adjuvant chemotherapy
for either patients with poor necrosis by the addition of
ifosfamide and etoposide (IE) or patients with good ne-
crosis by the addition of pegylated interferon-a-2b.13
Therefore, we recommend continuing MAP adjuvant
chemotherapy regardless of tumor necrosis. Posttherapy
follow-up is outlined in Figure 4A.
Question 4: What Is the Standard Primary
Therapy for Osteosarcoma Patients With
Equivocal Pulmonary Nodules?
Although most patients present with localized osteosarco-
ma, up to 30% present with metastatic disease, mostly in
the lungs. Equivocal pulmonary lesions are commonly
encountered, especially with high-resolution computed to-
mography scanning. Following guidelines proposed by
EURAMOS, we would consider 1 or more pulmonary/
pleural nodules 1 cm or 3 or more pulmonary nodu-
les 0.5 cm to be consistent with a diagnosis of metastatic
osteosarcoma, whereas smaller lesions are indeterminate
without pathologic confirmation. Patients with equivocal
lung nodules have 2 treatment options. One option is to
recommend wedge resection (with negative margins) at the
time of diagnosis. This strategy is preferred to needle biopsy
because it will confirm the pathology of the nodule and
also is the optimal therapy. The alternative is to observe the
nodules and assess the response to chemotherapy. If a pul-
monary nodule does not change size after chemotherapy
and there is evidence of a treatment effect on the primary
tumor, then we believe that the nodule is less likely to be a
tumor. Continued close surveillance after adjuvant chemo-
therapy is critical in these situations. Nodules that decrease
in size or mineralize with chemotherapy or that have no al-
ternative etiology (eg, endemic mycosis) should prompt the
clinician to recommend surgical resection. The optimal
timing for metastatectomy remains unclear. Our recom-
mendation is to proceed with pulmonary metastatectomy
after 4 cycles of MAP chemotherapy (followed by 2 more
cycles after surgery) or at the end of treatment (Fig. 2).14
Question 5: How Do You Treat Patients With
Recurrent Osteosarcoma of the Lung?
For patients who relapse, the first step is to confirm the
diagnosis of recurrent disease (Fig. 1). Patients with defin-
itive evidence of a pulmonary recurrence (nodules 1 cm,
multiple nodules 5mm) likely do not require a biopsy.
However, clinician judgment should dictate whether the
identity of a pulmonary nodule is unclear. In cases of
smaller nodules, management is typically based on the fea-
sibility of biopsy, and often, further observation is war-
ranted. Although we recognize that additional nodules
can develop, allowing time to clarify the etiology is not
felt to compromise the quality and goals of therapy. Once
recurrence has been confirmed, enrollment in a therapeu-
tic clinical trial is encouraged. Current clinical trials typi-
cally include patients with either unresectable disease or
adjuvant studies attempting to prevent recurrence after
the complete resection of pulmonary disease. However,
for those with an early relapse, although we would consid-
er a clinical trial, we would typically recommend IE.
We would prioritize a clinical trial for oligometastatic dis-
ease in the neoadjuvant setting using a new agent with
ifosfamide or IE. Preoperative chemotherapy is typically
recommended when there is more than 1 lesion at recur-
rence, the lesion or lesions are not surgically resectable, or
there has been a short time to recurrence. Although data
are limited and different time points have been used as the
cutoff, significantly worse outcomes have consistently
been described for patients who relapse<24 months after
their diagnosis.15,16 The Children’s Oncology Group has
also assessed survival after the relapse of osteosarcoma and
Review Article
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Figure 3. Pathway for treating newly diagnosed and relapsed Ewing sarcoma. CR, complete response; IE, ifosfamide and etopo-
side; PD, progressive disease; PR, partial response; SD, stable disease; VDC, vincristine, doxorubicin, and cyclophosphamide; XRT,
X-ray therapy.
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found similarly worse outcomes for those who relapse be-
fore 24 months (M. Isakoff, MD, oral communication,
October, 2016). For those with relapsed disease within
the first 24 months after the diagnosis, our first-line che-
motherapy recommendation is IE. Although an overall
survival benefit has not been fully assessed with this regi-
men, trials using IE have demonstrated response rates be-
tween 10% and 33%.17,18 We usually give 2
neoadjuvant cycles followed by 4 to 6 adjuvant cycles
according to the response and tolerability, and we are
more likely to recommend adjuvant cycles with favorable
radiographic changes and/or histologic demonstration of
pathologic necrosis (Fig. 2). However, there are not suf-
ficient data to drive these recommendations, and the ad-
verse effects of this regimen are significant. Thus, the
process of informed consent in this scenario is critically
important, and patients should be made aware of the
risks and potential benefits. After 2 cycles of chemother-
apy, surgical resection of all pulmonary nodules is
strongly encouraged because it is the only curative option
and the main determinant of the outcome.19 For those
patients with a resectable relapse more than 24 months
after the diagnosis, we typically do not add chemothera-
py and proceed with observation alone (Fig. 2). Compar-
ing the goal efficacy threshold for a given clinical trial
with an individual patient’s recurrence risk along with
the expected toxicity of a study regimen would be an im-
portant consideration when one is deciding whether or
not to recommend adjuvant chemotherapy trials for
patients with long-interval recurrences that have been
resected.
Question 6: What Is the Best Management
Strategy for Patients With Multiply Recurrent
or Unresectable Osteosarcoma?
The treatment of relapsed/refractory bone metastatic os-
teosarcoma is particularly challenging, and the progno-
sis is dismal. Multivariate analyses have revealed factors
that affect the risk of recurrence, including the size and
number of lesions, the time to recurrence, and the site,
and these may influence decision making for providers
and families. Although there may not be an absolute
right answer, there are options based on the balance of
toxicity, quality of life, and prognosis. For interested
patients with an adequate performance status, we
strongly advocate clinical trial enrollment in these situa-
tions and even prioritize phase 1 studies over nontrial
options (Table 1). The combination of gemcitabine and
docetaxel has been used for patients with refractory sar-
coma, including osteosarcoma, with partial responses
and stable disease seen in approximately 20% of patients
with refractory disease with a tolerable adverse-effect
profile.23 Data on sorafenib support its use as well, with
progression-free survival in a heavily pretreated, single-
arm patient cohort that exceeded 40% at 3 months.22 In
addition to chemotherapy, palliative radiotherapy may
be effective in the treatment of painful lesions. In our
discussions, anecdotal variations in the consensus, such
as trying therapies with low response rates for patients
with an excellent performance status when trials were
not available, did emerge.
Question 7: What Is the Role of Molecular
Testing and In Vivo Assays and When Is
Systemic Therapy No Longer Recommended for
a Patient With Bone Sarcoma?
Recent advances in molecular testing have led to the ex-
citing possibility that treatment choices might be direct-
ed on the basis of the identification of so-called
actionable mutations in a patient’s individual tumor.
Pediatric data publicly released by Foundation Medi-
cine35 have revealed a limited number of genomic
alterations found in any 1 tumor, and there are no pro-
spective data supporting the idea that choosing a thera-
py on the basis of this type of analysis improves the
response rate or survival. Thus, we would encourage
obtaining these data through participation in a clinical
trial so that the value of these analyses can be rigorously
tested and their effectiveness can be established or refut-
ed conclusively.
Deciding when further disease-directed therapy does
more harm rather than providing a chance for a benefit
remains a significant challenge, especially for patients
with a good performance status. In these circumstances,
molecular testing or testing with a xenograft-based drug
sensitivity assay is especially tempting because of the belief
that so-called targeted therapies are better tolerated than
traditional cytotoxic agents. Pursuing these approaches
would preferably be done in the context of a clinical trial,
but in the absence of a trial option, careful consideration
should be given to the paucity of prospective data and the
very real potential toxicity of even commonly prescribed
tyrosine kinase inhibitors. Deciding whether to recom-
mend further therapy on the basis of tests such as these, es-
pecially when the alternative is to discontinue any
additional cancer-directed treatment, should be made af-
ter extensive discussion with the patient and/or family and
preferably with the input of a molecular tumor board or
the equivalent. A full discussion of the ethics of deciding
when it is appropriate to recommend discontinuation of
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further attempts at systemic therapy is beyond the scope
of this review.
Question 8: What Is Needed to Accurately
Diagnose and Stage a Newly Diagnosed Ewing
Sarcoma Patient?
The incidence of Ewing sarcoma, like that of osteosarco-
ma, peaks in the teenage years. However, Ewing sarco-
ma is much more varied in primary tumor sites, with
one-half arising from the axial skeleton (eg, the pelvis or
ribs) and up to 20% originating in soft tissues.12 Our
staging strategy is described in Figure 1. Although bone
scans are less expensive and involve less radiation, posi-
tron emission tomography/computed tomography scans
have greater sensitivity and specificity for detecting met-
astatic disease and are, therefore, recommended.36 Be-
cause bone marrow metastases may occur, bilateral bone
marrow aspirates and biopsies have been routinely per-
formed for newly diagnosed patients. However, the
yield of finding marrow disease in patients without me-
tastases identified by positron emission tomography or
other imaging studies is extremely low, and outside a
clinical trial, a marrow evaluation is unnecessary for
these patients.37,38
Question 9: What Are the Key Components of
Therapy for Ewing Sarcoma and Should Therapy
Differ for Young Adults Versus Children?
Like the treatment for osteosarcoma, the treatment for
Ewing sarcoma combines local management of the prima-
ry tumor with chemotherapy to eradicate micrometastatic
disease. Most patients start treatment with neoadjuvant
chemotherapy for approximately 12 weeks, and this is fol-
lowed by local control with radiation, surgery, or both.
Further chemotherapy is then administered to reach a cu-
mulative total of at least 14 cycles. An early landmark
study showed the benefit of adding IE to the backbone of
vincristine, doxorubicin, and cyclophosphamide (VDC)
Figure 4. Recommendations for tumor surveillance after treatment. CBC indicates complete blood count; CMP, complete meta-
bolic panel; CT, computed tomography; CXR PA, chest X-ray, posterior anterior; PET, positron emission tomography.
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for younger patients with localized tumors.39 Outcomes
were further improved by compression of the schedule;
cycles were initiated every 2 weeks as tolerated instead of
every 3 weeks.40 This interval compression of VDC-IE is
now the standard of care in North America. In Europe,
drugs are grouped differently, and multiple cycles of vin-
cristine, ifosfamide, doxorubicin, and etoposide (VIDE)
constitute the standard chemotherapy regimen.41 A direct
comparison of VIDE and VDC-IE is being performed in
the ongoing Euro-Ewing 12 study (EudraCT number
2012-002107-17). In the largest retrospective studies, age
does not necessarily appear to be an independent prognos-
tic factor, and in general, young adults tolerate aggressive
chemotherapy similarly to children.42 For these reasons,
cooperative group trials have included patients up to the
age of 50 years. Therefore, we advocate the enrollment of
young adults into these trials or treatment according to a
pediatric regimen when therapy is outside a clinical study.
Question 10: What Factors Influence Local
Control of Ewing Sarcoma?
The choice of local control depends on the location of the
tumor and the ability to obtain negative surgical margins.
Resection of the tumor is usually performed if possible
with acceptable morbidity. Radiation can provide equally
durable local control of the tumor but does carry the asso-
ciated long-term risk of a secondary malignancy.43,44
However, if surgery would cause excess morbidity, radio-
therapy can provide similar treatment outcomes.45
In addition, radiotherapy is indicated for patients with
positive surgical margins. In Europe, radiotherapy is also
administered to patients with a poor histologic response
(90% necrosis) after neoadjuvant chemotherapy,
although this approach is not used by the authors. Post-
therapy follow-up is outlined in Figure 4B.
Question 11: What Is the Approach for
Metastatic Ewing Sarcoma?
Metastases are identified at diagnosis in approximately
one-fourth of Ewing sarcoma patients when the previous-
ly mentioned osteosarcoma lung nodule size criteria are
used. The decision to biopsy lung nodules is based on the
number and size of nodules as well as the overall staging
results. Because we recommend whole-lung radiotherapy
after the completion of chemotherapy for any patient with
pulmonary metastasis and we recognize that small nodules
often are quickly resolved with chemotherapy, biopsy of
equivocal lung nodules before treatment is started should
be considered if feasible.
The outcome of patients with disseminated Ewing
sarcoma is correlated with the extent of metastases. Those
with metastases limited to the lungs have an expected
5-year overall survival rate of 40%, whereas fewer than
20% of patients with bone and/or bone marrow metasta-
ses are long-term survivors.46 Enrollment in a clinical trial
is especially attractive for these patients because the stan-
dard treatment has not improved patient survival in deca-
des, and the intensification of conventional therapy or
even myeloablative chemotherapy with stem cell trans-
plantation has not been reported to be advantageous.
Combining conventional cytotoxic chemotherapy with
targeted drugs that have demonstrated single-agent activi-
ty is a reasonable strategy for investigation. Although the
use of extended low-dose maintenance therapy for
patients in remission after conventional treatment is in-
triguing, the benefits of this approach have not been estab-
lished, and this is not routinely used by the authors.47
Question 12: What Is the Approach to Relapsed
Ewing Sarcoma?
Most Ewing sarcoma relapses occur within 2 years of the
initial diagnosis, with metastases typically to the lungs and/
or bone. The patients at highest risk for recurrence are
those who had metastatic disease at the initial presentation,
pelvic tumors, or a poor histologic response to neoadjuvant
chemotherapy. The decision to biopsy suspicious lesions
depends on the context of risk factors, the extent of new
findings, and the possibility of a reasonable alternative ex-
planation for the findings. As a group, patients with recur-
rent Ewing sarcoma have a dismal overall prognosis, with
an estimated 5-year overall survival rate of <15%.48 How-
ever, certain prognostic factors, such as the timing of the
recurrence, may help to identify a subset of patients most
likely to benefit from salvage therapy. For example, al-
though patients with an early relapse (within 2 years of the
initial diagnosis) have a< 10% chance of long-term surviv-
al, up to one-fourth of those with a later relapse may po-
tentially be cured. Patients with local recurrences also tend
to fare better than those with systemic or combined recur-
rences, particularly if further local therapy can be adminis-
tered in addition to chemotherapy. In patients with
metastatic or recurrent disease with better long-term prog-
noses, stereotactic body radiotherapy may offer a quicker
treatment course that provides durable local control.10
Treatment decisions should take into account these
prognostic factors, prior therapy, and individual patient
characteristics, including organ function and the desire for
further treatment. In contrast to recurrent osteosarcoma,
for which surgical metastatectomy may be the only therapy
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used for some patients, chemotherapy is generally recom-
mended for all recurrent Ewing sarcoma patients (Fig. 3).
Enrollment in a clinical trial should be strongly considered,
even at the first relapse. Early-phase clinical trials are gener-
ally well tolerated in adolescents and young adults and of-
fer the chance to identify promising new therapies.
If the patient is not enrolled in a clinical trial, several
different treatment regimens may be considered (Table 1).
Overall, the consensus among authors is to use a combina-
tion of irinotecan and temozolomide as the first option,
primarily because of the favorable toxicity profile and the
option of giving both agents orally for the patient’s conve-
nience. When they are given orally, drug exposures similar
to those from intravenous administration can be seen as
long as the dose of irinotecan is adjusted to account for the
limited bioavailability and prophylactic cephalosporins are
used to reduce irinotecan-associated diarrhea.30 Interesting-
ly, the patterns of resistance to topotecan seem different
than the patterns of resistance to irinotecan, such that one
regimen may still have activity despite the failure of the
other. Responses to cyclophosphamide and topotecan ther-
apy were correlated with the relapse interval, with no
responses when the disease was progressing on prior thera-
py and with a rate greater than 50% response rate when 2
years had passed between the prior therapy and the initia-
tion of therapy.28 Once camptothecins have failed, possible
adverse effects, the patient’s performance status and mar-
row reserve, and the schedule of administration often affect
decisions about salvage therapy, especially with young
adults. For example, the frequency of intravenous chemo-
therapy administration, the need for growth factor and
transfusion support, and even the likelihood of certain tox-
icities such as nausea or alopecia may all factor into treat-
ment planning.
The median postrecurrence survival ranges from 9 to
17 months and depends on the extent of disease. Although
a cure is elusive, many patients experience some temporary
response or disease stabilization with the aforementioned
therapies. Patients with painful lesions typically respond
well to palliative doses of radiation.49 It is not unusual for
patients to receive more than 1 salvage regimen, and each
change in treatment allows additional opportunities for
clinical trial enrollment to be considered. Question 7
addresses our opinion on the role of emerging molecular
technologies and when additional care may not be in the
best interest of the patient. In addition, for patients who
have a declining performance status or insist on the conve-
nience of less complicated treatment regimens, both oral
etoposide and pazopanib have been reported to produce
occasional responses.34,50 Our current impression is that
exomic testing of tumor tissue with institutional or com-
mercially available platforms only rarely identifies action-
able mutations for this translocation-driven malignancy.
Finally, the use of high-dose chemotherapy with
autologous stem cell support has gained some interest
for treating patients with recurrent Ewing sarcoma, al-
though published studies have been limited by the lack
of an adequate control group.51,52 For example, patients
undergoing high-dose therapy must have previously
responded to initial conventional salvage treatments,
have organ function that will allow high-dose therapy,
and have adequate stem cells available for collection. Al-
though encouraging results may be seen in these select
patients, there is not sufficient evidence at present to
support this intensive approach as standard care for all
relapsed patients.
Question 13: What Is the Multimodal Approach
to Therapy for Chondrosarcomas?
There are several subtypes of chondroblastic malignancies
seen in the young adult years. These often present with
pain in the axial skeleton and have particular radiographic
features, including scalloping, to suggest the diagnosis.
Surgical management is critical for any chance of a
cure, and for resectable pulmonary metastases, we also ad-
vocate metastatectomy. Conventional chondrosarcoma is
chemotherapy-resistant, possibly because of the cartilagi-
nous matrix and difficulty with effective delivery of system-
ic agents to malignant cells, and adjuvant systemic therapy
would not be suggested.53 Radiation therapy is sometimes
recommended for positive margins. If these patients
develop metastases or have an unresectable local recurrence,
molecular testing, particularly for isocitrate dehydrogenase
mutations, and clinical trials would be the main con-
sideration.54 Other types of chondrosarcoma may be more
sensitive to chemotherapy, with dedifferentiated chondro-
sarcoma being treated similarly to osteosarcoma in the
young population and mesenchymal chondrosarcoma be-
ing treated similarly to Ewing sarcoma.55
In conclusion, we have described a consensus ap-
proach to the most common bone sarcomas of childhood,
adolescence, and young adulthood. Despite the many
options for any given situation, we report a consensus
from multiple centers and have outlined a general ap-
proach that can be taken for a variety of first-line and re-
lapse clinical scenarios.
Although there may not be one correct treatment
regimen, especially in the setting of relapse, we hope that
emphasizing clinical trials and presenting the modest or
limited activity of available regimens will lead to more
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consistent treatment and allow future improvements in
patient care.
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